Article Text

PDF

Building capacity for tobacco control research and policy
  1. F Stillman1,
  2. G Yang2,
  3. V Figueiredo3,
  4. M Hernandez-Avila4,
  5. J Samet1
  1. 1Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
  2. 2Peking Union Medical College, Beijing, PR China
  3. 3Instituto Nacional de Câncer, Rio de Janeiro, Brazil
  4. 4Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México
  1. Correspondence to:
 Dr Frances Stillman
 Institute for Global Tobacco Control, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St, W6027, Baltimore, MD 21205, USA; fstillma{at}jhsph.edu

Abstract

The Fogarty International Center (FIC) initiative, “International Tobacco and Health Research Capacity Building Program” represents an important step in US government funding for global tobacco control. Low- and middle-income countries of the world face a rising threat to public health from the rapidly escalating epidemic of tobacco use. Many are now parties to the Framework Convention on Tobacco Control (FCTC) and capacity development to meet FCTC provisions. One initial grant provided through the FIC was to the Institute for Global Tobacco Control (IGTC) at the Johns Hopkins Bloomberg School of Public Health (JHSPH) to support capacity building and research programmes in China, Brazil, and Mexico. The initiative’s capacity building effort focused on: (1) building the evidence base for tobacco control, (2) expanding the infrastructure of each country to deliver tobacco control, and (3) developing the next generation of leaders as well as encouraging networking throughout the country and with neighbouring countries. This paper describes the approach taken and the research foci, as well some of the main outcomes and some identified challenges posed by the effort. Individual research papers are in progress to provide more in-depth reporting of study results.

Statistics from Altmetric.com

Footnotes

  • Competing interest statement: The Institute for Global Tobacco Control receives financial support from GlaxoSmithKline and Pfizer pharmaceutical companies; however, neither Dr Stillman nor Dr Samet gain financially from the relationship

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.